Compare AU
Compare PAXX vs. DRUG
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Platinum Asia Fund Complex ETF (PAXX) and the Betashares Global Healthcare Currency Hedged ETF (DRUG). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
PAXX | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 3 | 64 |
Median incremental investment | $1,021.10 | $882.72 |
Median investment frequency | Monthly | Monthly |
Median total investment | $6,195.63 | $1,933.58 |
Average age group | > 35 | 26 - 35 |
Key Summary
PAXX | DRUG | |
|---|---|---|
Strategy | PAXX.AX was created on 2017-08-17 by Platinum. The fund's investment portfolio concentrates primarily on multi-strategy alternatives. The Fund aims to provide capital growth over the long-term by providing exposure to undervalued listed investments in the Asian region excluding Japan. | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. |
Top 3 holdings | Taiwan Semiconductor Manufacturing Co Ltd (8.29 %) JD.com Inc Ordinary Shares - Class A (5.79 %) Tencent Holdings Ltd (5.61 %) | BRL - BRAZILIAN REAL (0 %) AUD - AUSTRALIA DOLLAR (0 %) CHF - SWISS FRANC (0 %) |
Top 3 industries | Other (33.40 %) Information Technology (28.23 %) Consumer Discretionary (11.99 %) | Other (77.05 %) Communication Services (33.53 %) Health Care (22.79 %) |
Top 3 countries | China (46.18 %) Korea (17.74 %) Taiwan (10.79 %) | United States (71.71 %) Switzerland (8.14 %) Denmark (6.30 %) |
Management fee | 1.26 % | 0.57 % |
Key Summary
PAXX | DRUG | |
|---|---|---|
Issuer | Platinum | BetaShares |
Tracking index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD | |
Asset class | ETF | ETF |
Management fee | 1.26 % | 0.57 % |
Price | $4.89 | $7.48 |
Size | N/A | $168.727 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 5.11 % | 1.89 % |
Market | ASX | ASX |
First listed date | 14/09/2017 | 08/08/2016 |
Purchase fee | $6.50 | $6.50 |
Community Stats
PAXX | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 3 | 64 |
Median incremental investment | $1,021.10 | $882.72 |
Median investment frequency | Monthly | Monthly |
Median total investment | $6,195.63 | $1,933.58 |
Average age group | > 35 | 26 - 35 |
Pros and Cons
PAXX | DRUG | |
|---|---|---|
Pros |
|
|
Cons |
|
|
PAXX | DRUG |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Higher management fee | Lower management fee |
Lower price growth | Higher price growth |
Higher distribution yield | Lower distribution yield |